S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Price, News & Analysis

$20.29
-0.13 (-0.64%)
(As of 03/28/2024 ET)
Today's Range
$20.03
$20.68
50-Day Range
$18.44
$26.39
52-Week Range
$12.32
$32.10
Volume
469,129 shs
Average Volume
706,552 shs
Market Capitalization
$877.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$124.00

Cassava Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
511.1% Upside
$124.00 Price Target
Short Interest
Bearish
30.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.27mentions of Cassava Sciences in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.01) to $1.67 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

322nd out of 938 stocks

Pharmaceutical Preparations Industry

138th out of 417 stocks

SAVA stock logo

About Cassava Sciences Stock (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock Price History

SAVA Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Cassava Sciences (NASDAQ:SAVA) Trading Down 5.1%
SAVA Apr 2024 23.500 call
SAVA Jun 2025 30.000 call
SAVA Jun 2025 10.000 put
SAVA Apr 2024 20.500 put
SAVA Mar 2024 19.500 put
SAVA Mar 2024 11.000 put
SAVA Mar 2024 17.500 call
SAVA Jan 2025 2.500 call
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAVA
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$124.00
High Stock Price Target
$124.00
Low Stock Price Target
$124.00
Potential Upside/Downside
+511.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-97,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.26 per share

Miscellaneous

Free Float
39,335,000
Market Cap
$876.93 million
Optionable
Optionable
Beta
-0.42
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Remi Barbier (Age 64)
    Founder, Chairman, President & CEO
    Comp: $1.11M
  • Mr. Eric J. Schoen (Age 56)
    Chief Financial Officer
    Comp: $426.61k
  • Mr. R. Christopher Cook (Age 59)
    Senior VP, Company Secretary & General Counsel
    Comp: $457.64k
  • Dr. James W. Kupiec M.D. (Age 70)
    Chief Medical Officer
    Comp: $400k
  • Dr. George Thornton Ph.D.
    Senior Vice President of Technology
  • Mr. Michael Zamloot
    Senior Vice President of Technical Operations
  • Dr. Michael Marsman Pharm.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D.
    Senior Vice President of Neuroscience

SAVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for Cassava Sciences' stock. Their SAVA share price targets range from $124.00 to $124.00. On average, they predict the company's stock price to reach $124.00 in the next year. This suggests a possible upside of 511.1% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2024?

Cassava Sciences' stock was trading at $22.51 at the beginning of the year. Since then, SAVA stock has decreased by 9.9% and is now trading at $20.29.
View the best growth stocks for 2024 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10.

What ETFs hold Cassava Sciences' stock?
When did Cassava Sciences' stock split?

Cassava Sciences's stock split on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.51%), Vanguard Group Inc. (5.38%), Gallacher Capital Management LLC (1.38%), Northern Trust Corp (0.92%), Charles Schwab Investment Management Inc. (0.73%) and Nuveen Asset Management LLC (0.66%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAVA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners